---
title: "BUCHANG PHARMA: Pomegranate Cloud Medical is listed on the NASDAQ stock exchange in the United States"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/260892392.md"
description: "According to the Zhitong Finance APP, BUCHANG PHARMA announced that its affiliated company Guangzhou Qilekang Digital Health Medical Technology Co., Ltd. (hereinafter referred to as \"Qilekang Digital Medical\") has a substantial controlling company POMDOCTOR LIMITED Shiliu Cloud Medical Co., Ltd. (hereinafter referred to as \"Shiliu Cloud Medical\") which will be listed on the NASDAQ stock exchange in the United States using the VIE model on October 8, 2025 (New York time), with the stock code: POM"
datetime: "2025-10-13T12:06:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/260892392.md)
  - [en](https://longbridge.com/en/news/260892392.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/260892392.md)
generator: "portal-rs"
---

# BUCHANG PHARMA: Pomegranate Cloud Medical is listed on the NASDAQ stock exchange in the United States

According to the Zhitong Finance APP, BUCHANG PHARMA (603858.SH) announced that its affiliated company Guangzhou Qilekang Digital Health Medical Technology Co., Ltd. (hereinafter referred to as "Qilekang Digital Medical") has a substantial holding company POMDOCTOR LIMITED Shiliu Cloud Medical Co., Ltd. (hereinafter referred to as "Shiliu Cloud Medical") which will be listed on the NASDAQ stock exchange in the United States using the VIE model on October 8, 2025 (New York time), with the stock code: POM

### Related Stocks

- [603858.CN](https://longbridge.com/en/quote/603858.CN.md)

## Related News & Research

- [TLV: Strong H1 2026 profit growth and capital strength amid macroeconomic challenges](https://longbridge.com/en/news/296790736.md)
- [CHINA TELECOM 1H26 Net Profit Fades 14.9% to RMB19.588B, Beats Forecast; Interim DPS HKD0.1606](https://longbridge.com/en/news/296462591.md)
- [Piller signs contract with Cosun Beet for V-RISE upgrade at Dutch sugar plant](https://longbridge.com/en/news/296751243.md)
- [DIMRI: H1 2026 net profit rose to ₪495.6M on revenue of ₪780.5M, with robust liquidity and equity](https://longbridge.com/en/news/296448412.md)
- [Rapala VMC: Strong H1 sales and profit growth led to upgraded full-year outlook amid ongoing trade risks](https://longbridge.com/en/news/296480810.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**